Selective mRNA expression of HMSD and HMSD-v. (A) Total HMSD expression was determined by real-time quantitative PCR in various normal tissues and malignant hematopoietic cell lines using a primer-probe set that detects the exon 3-4 boundary. Targeted mRNA expression in the recipient B-LCL is set as 1.0. In the top dotted plot graph, cDNAs prepared from CD34⁺ subsets of primary leukemic cells and CD138⁺ subsets of primary MM cells, freshly isolated hematopoietic cells, their subpopulations, immature and mature DCs, activated B and T cells, freshly isolated CD34⁺ bone marrow cells, and primary cell cultures were similarly analyzed. Values in the parentheses indicate the number of the individuals tested. In the bottom and middle panels, cDNAs prepared from 16 hematologic malignant cell lines are shown. SUDHL4 and SUDHL10 are derived from B-cell non-Hodgkin lymphoma; NALM6 from acute B-lymphocyte leukemia; NAMALWA and Raji from Burkitt lymphoma; KMS18 and KMS28 from multiple myeloma (MM); Jurkat and MOLT4 from acute T-lymphocyte leukemia; U937 from histiocytic lymphoma; HL60, KG-1, NKM-1, NOMO1, and HEL92.1.7 from acute myeloid leukemia; and MEGO1 from chronic myeloid leukemia (blast crisis). (B) cDNAs of 15 normal tissue samples purchased from Clontech (MTC panels human I and II) were analyzed for total HMSD expression (top panel) and CD45 mRNA expression (bottom panel). Messenger RNA expression in the recipient B-LCL is set as 1.0. (C) HMSD-v expression levels (○) were compared with total HMSD expression levels (●) using a primer-probe set that detects the exon 1-3 boundary specific for HMSD-v mRNA. Among primary hematopoietic cells shown in the top of panel A, cells that were found to be heterozygous for ACC-6 allele were further selected and tested. Paired samples are linked.